Astute is the maker of Nephrocheck, an immunoassay test for biomarkers predicting acute kidney injury.
The Codex4SMEs project, which has a €3.1 million budget, involves seven countries to increase cooperation in Europe's northwest region to develop companion diagnostics.
The LITMUS project will bring together clinicians and researchers from academia and pharma to develop, validate, and quantify better biomarkers for testing NAFLD.
The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples.
Bioinformatics firm Berg is combining multi-omics data from the Department of Defense's Center for Prostate Disease Research in search of biomarkers.
CSO Phil Stephens said the firm is finding specific genomic alterations that appear to affect sensitivity to immunotherapies, as it also advances overall mutation burden testing.
A series of new studies contain clues to predicting heart disease in healthy individuals and future problems in those already treated for cardiovascular conditions.